ChipCare
Date | Investors | Amount | Round |
---|---|---|---|
$1.2m | Grant | ||
N/A | $2.1m | Angel | |
$5.0m | Series A | ||
$18.0m | Series B | ||
Total Funding | AUD40.6m |
Related Content
Recent News about ChipCare
EditChipCare, based in Toronto, develops a highly versatile point of care (POC) diagnostic platform designed to streamline the sample-to-action workflow in clinical settings. Utilizing a patented approach for analyte detection, the platform can perform multiple classes of assays, including cell surface markers, proteins, and nucleic acids, from easily collected samples such as urine. The primary focus is on sexually transmitted infections (STIs) in the North American and European markets. Healthcare workers in various medical settings, including STI clinics, pharmacy clinics, physicians' offices, and remote health locations, can rapidly and accurately perform lab-quality tests to aid in diagnosing or monitoring a wide range of infectious diseases. This enables physicians to provide true test and treat options, significantly enhancing patient care quality while reducing healthcare costs. ChipCare employs 20 people in downtown Toronto, bringing together multiple engineering disciplines and assay development scientists with experience in product development and commercialization. The company is always on the lookout for enthusiastic engineers, scientists, and software developers.
Keywords: point of care diagnostics, multiplexed assays, STI testing, analyte detection, healthcare innovation, clinical workflow, patient care, cost reduction, medical diagnostics, Toronto-based.